Skip to content

High Protein Diet and Atherosclerosis

Dissecting the Impact of Dietary Protein on Macrophage MTOR Signaling and Atherosclerosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05235464
Acronym
HPA
Enrollment
24
Registered
2022-02-11
Start date
2023-03-13
Completion date
2028-03-31
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas lean protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.

Interventions

Standard meal

OTHERHigh animal protein meal

Meal with high animal protein content

OTHERHigh plant protein meal

Meal with high plant protein content

OTHERHigh plant protein meal with additional leucine

Meal with high plant protein content and additional leucine

Sponsors

University of Missouri-Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Randomized cross-over study

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* \>=45 and \<=75 years of age * body mass index \>=25.0 and \<40.0 kg/m2

Exclusion criteria

* \<45 and \>75 years of age * body mass index \<25.0 or \>39.9 kg/m2 * plasma triglyceride \<125 mg/dl * history of or current significant organ system dysfunction * allergies or intolerances to meal ingredients * use of medications or dietary supplements that could confound the study outcomes * engaged in regular structured exercise \>150 min per week * alcohol use disorder * premenopausal women * persons who smoke * prisoners * inability to grant voluntary informed consent

Design outcomes

Primary

MeasureTime frameDescription
Monocyte p-S6 contentchange from at 1 hour before meal intake and 3 hours after the mealphospho-S6 content in monocytes

Countries

United States

Contacts

Primary ContactBettina Mittendorfer, PhD
b.mittendorfer@missouri.edu6186103465

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026